Skip to main content
    1. Congress Materials

    • Society of Dermatology Physician Assistants (SDPA) Summer, 2026

    Filter
    Close
    Filter
    ⁨⁨⁨⁨Keyword (eg, author, condition)
    Content type:
    Clear filters
    Bimekizumab Pharmacokinetics, Safety, and Efficacy in Adolescent Patients with Moderate to Severe Plaque Psoriasis: Data from the Initial Treatment Period of the Open-label BE CONNECTED Phase 2 Study
    Amy Paller, Jacek C. Szepietowski, Jolanta Węgłowska, et al.
    Poster
    Bimekizumab On-Treatment Remission as Defined by the National Psoriasis Foundation: 1-Year Results Versus Ustekinumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis
    April Armstrong, Lourdes Pérez-Chada, Mark Lebwohl, et al.
    Poster
    Bimekizumab Leads to Sustained Flare-Free Status in Moderate to Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT
    Steven Daveluy, Haley B. Naik, Ziad Reguiai, et al.
    Poster
    Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT
    Christopher J. Sayed, Martina L. Porter, Alejandro Molina-Leyva, et al.
    Poster